Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.62 |
| ▸ | PGR | P06401 | 8/20 | 0.62 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7694911 | 0.84 | ROCK2 (0.49) | NR3C1PGRNR3C2MAPTKDM4E | |
| SCHEMBL29606212 | 0.82 | MAPT (0.66) | NR3C1PGRNR3C2MAPTKDM4E | |
| SCHEMBL4184355 | 0.81 | PGR (0.70) | NR3C1PGRNR3C2MAPTKDM4E | |
| SCHEMBL4179509 | 0.81 | MEN1 (0.65) | NR3C1PGRNR3C2MAPTKDM4E | |
| SCHEMBL5764438 | 0.81 | MAPT (0.68) | NR3C1PGRNR3C2MAPTKDM4E | |
| SCHEMBL4179300 | 0.79 | KMT2A (0.59) | NR3C1PGRNR3C2MAPTKDM4E | |
| SCHEMBL291078 | 0.77 | PGR (1.00) | NR3C1PGRNR3C2MAPTKDM4E | |
| SCHEMBL6086189 | 0.77 | MAPT (0.71) | NR3C1PGRNR3C2MAPTKDM4E | |
| SCHEMBL22271481 | 0.77 | MAPT (0.60) | NR3C1PGRNR3C2MAPTKDM4E | |
| SCHEMBL10751140 | 0.77 | BAZ2B (0.55) | NPC1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | UNIVERSITY OF HAWAII (US) | 2022-04-12 | — | — | US | disclosed |
| CN-111356456-A | 2-arylsulfonamido-iV-arylacetamide derived Stat3 inhibitor | 夏威夷大学 | 2020-06-30 | — | — | CN | disclosed |
| WO-2018136935-A1 | 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS | UNIVERSITY OF HAWAII (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | STAT3, JAK2, STAT5A | NR3C1 978/4885PGR 1571/4885NR3C2 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.